TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04201106

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Open Label Placebo with Rationale
Description: In the OLP + rationale group, the participants will be prescribed to take placebos for 2 weeks with the standard 4-point accompanying rationale: (1) the placebo effect is powerful, e.g. in clinical trials placebos are roughly 80% as effective as antidepressants; (2) classical conditioning is a possible mechanism for automatic self-healing - meaning that the body can automatically respond to taking placebo pills like Pavlov's dogs who salivated when they heard a bell; (3) placebo-treated patients who are more compliant have better outcomes, therefore the placebos should be taken faithfully; and (4) positive expectations increase placebo effects, but it is OK to have doubts.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Open Label Placebo without Rationale
Description: In the OLP without rationale group, the adolescents will be asked to take placebos for 2 weeks but they will be told that the pills contain inert substance and do not have any pharmacological effect.
Study: NCT02727907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCD-033 (interferon beta 1a)
Description: Subcutaneous injection of BCD-033, 44 µg (0,5 ml) 3 times per week, every other day, for 92 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rebif (interferon beta 1a)
Description: Subcutaneous injection of Rebif, 44 µg (0,5 ml) 3 times per week, every other day, for 48 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection of placebo, 0,5 ml 3 times per week, every other day, for12 weeks
Study: NCT04127695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo ABBV-0805
Description: Placebo ABBV-0805 administered by IV infusion.
Study: NCT02006914

Intervention type: DIETARY_SUPPLEMENT
Intervention: Chromium Picolinate
Description: Subjects will be asked to take chromium picolinate; 2 tablets per day, 1000 mcg or a placebo for a total of 8 weeks.
Study: NCT00806039

Intervention type: OTHER
Group type: OTHER
Intervention: Early Renal Involvement
Description: Renal Consultation
Study: NCT01696370

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trimetazidine
Description: Trimetazidine 20mg three times per day for 3 months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: one capsule three times per day for 3 months
Study: NCT01451489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FK506
Description: FK506:0.05-0.1mg/kg/d

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: CTX 750mg/m2 per month in the induction phase,then 750mg/m2 every 2 month for 3 times,then 750mg/m2 every 3 months.
Study: NCT00189839

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tacrolimus
Description: Immunosuppression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: Immunosuppression
Study: NCT01528930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amikacin
Description: 500 mg, once daily for 2 years
Study: NCT02339246

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prograf vs Envarsus XR vs Astagraf XL
Description: prograf vs Envarsus XR vs Astagraf XL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prograf vs Astagraf XL vs Envarsus XR
Description: Prograf vs Astagraf XL vs Envarsus XR
Study: NCT02544126

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electronic Self-Management Resource Training for Mental Health
Description: eSMART-MH is a software, which is set in a 3-D virtual primary care office environment in which a subject interacts with avatar virtual healthcare staff (medical receptionist, medical assistant, providers, and a virtual healthcare coach). The avatars are programed to behave like humans. The subject moves through the 3-D virtual primary care office and encounters virtual healthcare staff and providers. The subject practices discussing depressive symptoms with avatar healthcare providers and practices self-management skills related to symptoms of depression.The subject also interacts with the health care coach. The health care coach provides the subject with real-time strategies to enhance communication with healthcare providers during their virtual office visit. Overtime, coaching is decreased to build the the subject's self-confidence. eSMART-MH will be used once a month, for three months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Screen-based health education
Description: Screen-based health education will be used and cover topics like depression, nutrition, physical activity, and sleep hygiene at the same frequency as the eSMART-MH intervention, which is used once a month, for three months.
Study: NCT00567853

Intervention type: DEVICE
Group type: OTHER
Intervention: Implantation of the MEMO 3D Annuloplasty Ring
Description: Implantation of the MEMO 3D Annulopalsty Ring for mitral valve repair.
Study: NCT02120066

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Vitrectomy for submacular hemorrhage

Intervention type: DRUG
Group type: OTHER
Intervention: subretinal injection of tissue-plasminogen activator
Study: NCT02722226

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulation
Description: High fidelity simulation based sedation learning program

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Airway management
Description: Workshop on using airway management and oxygenation devices.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Crisis resource management
Description: Learning crisis resource management principles
Study: NCT01509235

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chest physiotherapy
Description: The whole exercise session consisted of three short period of exercise of 5 minutes each entirely done under the physiotherapists' supervision (FA).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Chest physiotherapy
Description: The whole exercise session consisted of three short period of exercise of 5 minutes each entirely done under the physiotherapists' supervision (FA).
Study: NCT01398371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Withdrawal of digoxin
Description: Participants currently receiving digoxin for heart failure will have their digoxin stopped for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Digoxin
Description: Stable digoxin therapy which produces a digoxin plasma level of 0.4-0.8.
Study: NCT02673918

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based upper-body rehabilitation with online support
Description: Participants will be given written educational material, in which the physiotherapist marks the exercises specifically recommended for the individual patient. In addition, participants will get a personal password giving access to the BRECOR website for 12 weeks. The website contains professionally filmed videos of upper-body rehabilitation exercises (joint mobility and muscle strength) and instructions in scar tissue massage and manual lymph drainage. Furthermore, mindfulness sessions and additional information about prevention and early detection of late effects after breast cancer treatment are available on the website.~On average, participants will complete three rehabilitation exercises 5-7 times weekly with an anticipated duration of approximately 20 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based upper-body rehabilitation with online support
Description: Participants will be given written educational material, in which the physiotherapist marks the exercises specifically recommended for the individual patient. In addition, participants will get a personal password giving access to the BRECOR website for 12 weeks. The website contains professionally filmed videos of upper-body rehabilitation exercises (joint mobility and muscle strength) and instructions in scar tissue massage and manual lymph drainage. Furthermore, mindfulness sessions and additional information about prevention and early detection of late effects after breast cancer treatment are available on the website.~On average, participants will complete three rehabilitation exercises 5-7 times weekly with an anticipated duration of approximately 20 minutes.
Study: NCT02021942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOM230 LAR
Description: SOM230 LAR in a dosage of 60 mg is administered i.m. once every 4 weeks.
Study: NCT00818792

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary stent
Description: Comparison of bare-metal stent (Vision) and drug-eluting stent (Xience V)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary stent
Description: Comparison of bare-metal stent (Vision) and drug-eluting stent (Xience V)
Study: NCT02604849

Intervention type: DRUG
Intervention: Neomycin
Study: NCT00004144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bryostatin 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Study: NCT00577122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone progesterone acetate (MPA)
Description: 1000 mg po daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone with Cyclophosphamide + Methotrexate
Description: Medroxyprogesterone Acetate Dose 1000 mg po daily Cyclophosphamide Dose 50 mg po daily Methotrexate Dose 2.5 mg po daily Days 1 and 2 of each week
Study: NCT02604849

Intervention type: DRUG
Intervention: Streptomycin

Intervention type: DRUG
Intervention: Gentamicins
Study: NCT05184530

Intervention type: DRUG
Intervention: Evolocumab 140 MG/ML
Description: 140 mg per two weeks, subcutaneous injection

Intervention type: DRUG
Intervention: Evolocumab 140 MG/ML
Description: 140 mg per two weeks, subcutaneous injection
Study: NCT03359174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: All-trans retinoic acid
Description: Fixed low dose of ATRA 10 mg twice daily for 24 weeks.
Study: NCT02741245

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe 10 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 2.5 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 2.5 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin 2.5 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin 2.5 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for Ezetimibe

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for Ezetimibe

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for Rosuvastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Rosuvastatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for Rosuvastatin
Study: NCT02401347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib Tosylate
Description: Participants receive Talazoparib tosylate at 1 mg by mouth daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib Tosylate
Description: Participants receive Talazoparib tosylate at 1 mg by mouth daily.
Study: NCT04416412

Intervention type: OTHER
Intervention: Immunofluorescence Imaging
Description: Patients will be administered FDA approved ICG through intravenous injection and imaged by a FDA approved surgical microscope (Spy Elite) which is 0.5 meter away from the subject. Both ICG fluorescence and the two imaging systems have been used for routine clinical practice for many years. Figure (a) shows the Schematic sketch of the imaging systems. ICG fluorescence imaging utilizes intravenously injected ICG, which is a fluorescent dye that is FDA-approved for clinical use, illuminated with near-infrared light. The ICG dye is indirectly activated and the dynamic fluorescence due to bone perfusion can be captured by a video rate imaging system.
Study: NCT01685567

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MICHI NPS+f
Description: Cerebral protection with carotid flow reversal
Study: NCT02591108

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neuromuscular Block Aid
Description: Neuromuscular Block Aid, is a quantitative mechansim for collecting the the train-of-four and can be kept in an electronic medical record, also known as a train-of-four monitor, is used to assess neuromuscular transmission when neuromuscular blocking agents (NMBAs) are given to block musculoskeletal activity. By assessing the depth of neuromuscular blockade, peripheral nerve stimulation/monitoring can ensure proper medication dosing and thus decrease the incidence of side effects. Peripheral nerve stimulation is most commonly used for ongoing monitoring in the intensive care unit (ICU).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular Block Aid
Description: Neuromuscular Block Aid, is a quantitative mechansim for collecting the the train-of-four and can be kept in an electronic medical record, also known as a train-of-four monitor, is used to assess neuromuscular transmission when neuromuscular blocking agents (NMBAs) are given to block musculoskeletal activity. By assessing the depth of neuromuscular blockade, peripheral nerve stimulation/monitoring can ensure proper medication dosing and thus decrease the incidence of side effects. Peripheral nerve stimulation is most commonly used for ongoing monitoring in the intensive care unit (ICU).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care: Microstim Plus
Description: A peripheral nerve stimulator, also known as a train-of-four monitor, is used to assess neuromuscular transmission when neuromuscular blocking agents (NMBAs) are given to block musculoskeletal activity. By assessing the depth of neuromuscular blockade, peripheral nerve stimulation/monitoring can ensure proper medication dosing and thus decrease the incidence of side effects. Peripheral nerve stimulation is most commonly used for ongoing monitoring in the intensive care unit (ICU).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard of Care: Microstim Plus
Description: A peripheral nerve stimulator, also known as a train-of-four monitor, is used to assess neuromuscular transmission when neuromuscular blocking agents (NMBAs) are given to block musculoskeletal activity. By assessing the depth of neuromuscular blockade, peripheral nerve stimulation/monitoring can ensure proper medication dosing and thus decrease the incidence of side effects. Peripheral nerve stimulation is most commonly used for ongoing monitoring in the intensive care unit (ICU).
Study: NCT03291483

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: whole body vibration
Description: whole body vibration is a mechanical stimulus characterized by oscillatory movements.Whole body vibration's potential beneficial effects occurs by transmission of mechanical and sinusoidal vibrations to the whole body through the feet.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: plyometric training
Description: Plyometric exercises refers to performance of stretch-shortening cycle (SSC) movements that involve a high-intensity eccentric contraction immediately after a rapid and powerful concentric contraction.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: plyometric training
Description: Plyometric exercises refers to performance of stretch-shortening cycle (SSC) movements that involve a high-intensity eccentric contraction immediately after a rapid and powerful concentric contraction.
Study: NCT02354534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate Suppositories

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate Suppositories

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate Suppositories

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate Suppositories
Study: NCT05357716

Intervention type: DEVICE
Intervention: HeartWatch
Description: The HeartWatch arm band provides continuous, high-quality single lead electrocardiograph (ECG) data in a variety of environments. The ECG data is transmitted via Bluetooth and stored on the user's smartphone. It is then uploaded to the cloud for subsequent analysis using either a commercial ECG software package or a customized software package from HelpWear.

Intervention type: DEVICE
Intervention: HeartWatch
Description: The HeartWatch arm band provides continuous, high-quality single lead electrocardiograph (ECG) data in a variety of environments. The ECG data is transmitted via Bluetooth and stored on the user's smartphone. It is then uploaded to the cloud for subsequent analysis using either a commercial ECG software package or a customized software package from HelpWear.

Intervention type: DEVICE
Intervention: Event Recorder
Description: A standard 1 or 2-lead Sirona Event Recorder will be used to collect high-resolution data. Subjects will be asked to wear the clinical monitor for at least 48 hours and no longer than 84 hours. ECG signals will be continuously collected as long as the skin patches are attached to the skin and the recorder is properly connected to the wires.

Intervention type: DEVICE
Intervention: Holter Monitor
Description: A standard 5-lead SEER Holter will be used to collect 3-channels of high-resolution data. Subjects will be asked to wear the clinical, conventional monitor for at least 36 hours and no longer than 60 hours. During this time ECG signals will be continuously collected.
Study: NCT03679728

Intervention type: BEHAVIORAL
Intervention: First trimester
Description: Analysis of sensorimotor outcomes

Intervention type: BEHAVIORAL
Intervention: Second trimester
Description: Analysis of sensorimotor outcomes
Study: NCT02982564

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Program Low Intensity
Description: This arm includes a low-intensity intervention and will have a duration of six months. Participants will be provided with a heart rate monitor to train at the intensity according to group assignment. Progression for both programs in the endurance component will be slower and more gradual for deconditioned participants, and may require multiple shorter periods (5-10 minutes) with rest intervals.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Program Moderate Intensity
Description: This arm includes a moderate-intensity intervention and will have a duration of six months. Participants will be provided with a heart rate monitor to train at the intensity according to group assignment. Progression for both programs in the endurance component will be slower and more gradual for deconditioned participants, and may require multiple shorter periods (5-10 minutes) with rest intervals.
Study: NCT02747186

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Intraoral maxillary field block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Intraoral maxillary field block
Study: NCT01363089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine
Description: 30 mg of intranasal ketorolac tromethamine (one 100 µL spray into each nostril of a 15%, pH 7.2 solution)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxymetazoline hydrochloride
Description: Single intranasal dose of oxymetazoline hydrochloride (Afrazine®) (3 sprays of a 0.05% solution into each nostril) followed 30 minutes later by 30 mg of intranasal ketorolac tromethamine (one 100 µL spray into each nostril of a 15%, pH 7.2 solution)
Study: NCT03076138

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gene-activated matrix (OCP + plasmid DNA with VEGF gene)
Description: Bone grafting procedure with investigated medical device
Study: NCT01209897

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking cessation booklet

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking cessation booklet
Study: NCT04423055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etonogestrel contraceptive implant
Description: Place etonogestrel contraceptive implant.
Study: NCT01640782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan, Leucovorin, 5-Fluorouracil, Docetaxel, Cisplatin
Description: * Irinotecan (CPT-11) 180 mg/m2, given as 60 min. i.v. infusion on day 1 every 2 weeks followed by~* Leucovorin (LV) 100 mg/m2, given as a 2h i.v. infusion on days 1 and 2 every 2 weeks followed by~* 5-Fluorouracil (5-FU) 400 mg/m2 given as bolus, and then 5-Fluorouracil (5-FU) 600 mg/m2 given as a 22h continuous infusion on days 1 and 2, every 2 weeks for 4 administrations.~After 3 weeks from last infusion:~* Docetaxel (TXT) 75 mg/m2, given as a 1h i.v. infusion on day 1 followed by~* Cisplatin (CDDP) 75 mg/m2, given as a 1h i.v. infusion on.day 1, every 3 weeks, for 3 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin, 5-Fluorouracil
Description: * Leucovorin (LV) 100 mg/m2, given as a 2h i.v. infusion on days 1 and 2 every 2 weeks followed by~* 5-Fluorouracil (5-FU) 400 mg/m2 given as bolus, and then 5-Fluorouracil (5-FU) 600 mg/m2 given as a 22h continuous infusion on days 1 and 2, every 2 weeks for 9 administrations.
Study: NCT02586623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Droxidopa capsules
Description: 100, 200 or 300 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Droxidopa capsules
Description: 100, 200 or 300 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules
Study: NCT04485546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cenegermin-bkbj
Description: Cenegermin-bkbj ophthalmic solution administered as one drop in affected eye(s) every 2 hours 6 times daily for 8 weeks
Study: NCT03077542

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: haploidentical stem cell transplant
Description: haploidentical stem cell transplant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: conditioning regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: conditioning regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentostatin
Description: conditioning regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: conditioning regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Description: conditioning regimen

Intervention type: DRUG
Group type: OTHER
Intervention: Filgrastim
Description: A haploidentical relative donor will receive filgrastim (G-CSF) 10 to 16 µg/kg/d subcutaneously or intravenously for up to 6 days with apheresis collections of peripheral blood hematopoietic progenitor cells (PBPC) after the 5th day (and after the 6th day if required).
Study: NCT01333293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: injections
Description: subcutaneous injections

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: injections
Description: subcutaneous injections